Quintiles announced that it has contributed open source code to the Apple ResearchKit, which was launched earlier this year. The code, which was submitted through and available on GitHub, has been approved by Apple for incorporation into ResearchKit.
The overall enhancements provide ResearchKit app developers with extensions that support additional capabilities. Quintiles’ contribution to ResearchKit should enable the apps it produces with the framework to further engage patients participating in clinical research.
Technically, the following code was contributed:
Location Question Type: This pull request adds support for a new location question and answer type. It can be used as a single question step and/or in a form task. You may have multiple entries in the form task and while interacting with each individual form item, the map will hide or show depending on your current selection. The location question handles the permission request for accessing the devices current location, when using the current location button. It will reverse geocode the current location value to an address and fill it in the question answer field.â¨
Validated Text: This pull request adds support for generic validated text answers that can be used in both form item questions and survey question steps. It takes a regex expression, which is optional, that is used for validation along with an error string that will be displayed when the validation fails.â¨
Wait Task: This pull request adds support for a generic wait task that can be used a task or in-between steps allowing you to process or update additional data. It supports both indeterminate and determinate progress views that tint accordingly and a place for status updates.
The work Quintiles is doing with Apple and its contribution to ResearchKit is part of Quintiles’ commitment to technology leadership within the biopharma services industry.
Read the full release, with links to accompanying videos.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.